OBJECTIVE: To assess the efficacy and safety of vaccination against @entity778 in @entity1 with @entity309 ( @entity309 ), @entity1252 ( @entity1252 ), @entity5144 ( @entity5144 ), and @entity1691 ( @entity1691 ) compared with healthy controls. METHODS: The study population comprised 41 @entity309 @entity1 , 21 @entity1252 @entity1 , 17 @entity5144 @entity1 , 15 @entity1691 @entity1 , and 25 healthy controls. All were vaccinated using the Novartis @entity1156 -adjuvanted H1N1v monovalent influenza vaccine. The immunogenicity of the vaccine was assessed on day 1 and again 4 weeks later by hemagglutination inhibition assay. Geometric mean titers and seroconversion rates were calculated for each group. The safety of the vaccine was evaluated using the 28-joint Disease Activity Score (DAS28) for @entity309 and @entity5144 , the @entity1252 Activity Index (SLEDAI), and the Bath @entity1691 Activity Index (BASDAI). RESULTS: The proportion of baseline protective levels of antibodies against H1N1 was similar in all but the @entity1691 group, in which it was lower. The geometric mean titers increased significantly in all 5 groups. A substantial proportion of @entity1 and controls responded to the vaccine. The healthy controls demonstrated a better response than each of the other groups: 84% versus 56% for @entity309 , 67% for @entity1252 , 59% for @entity5144 , and 53% for @entity1691 . Multivariate logistic regression analysis identified @entity309 and @entity5144 as parameters of significantly lower response. The DAS28, BASDAI, and SLEDAI remained unchanged after vaccination. CONCLUSION: Vaccination against pandemic H1N1 using an adjuvanted H1N1v monovalent influenza is safe and induced an appropriate response in @entity1 with @entity309 , @entity1252 , @entity5144 , and @entity1691 .

Efficacy and safety of vaccination against pandemic 2009 XXXX among @entity1 with rheumatic diseases.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity778 :: ('MESH:D015658', 'Disease') :: ['pandemic H1N1 virus'] @entity1156 :: ('MESH:C089950', 'Chemical') :: ['MF59'] @entity1252 :: ('MESH:D008180', 'Disease') :: ['SLE', 'systemic lupus erythematosus', 'Systemic Lupus Erythematosus Disease'] @entity5144 :: ('MESH:D015535', 'Disease') :: ['PsA', 'psoriatic arthritis'] @entity1691 :: ('MESH:D013167', 'Disease') :: ['Ankylosing Spondylitis Disease', 'ankylosing spondylitis', 'AS'] @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'RA']
@entity778 :: (MESH:D015658,Disease) :: ['influenza A (H1N1) virus']
